{"id":"jns001","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of JNS001 is not publicly well-characterized in available literature, it is being developed by Janssen as an immunomodulatory therapeutic in Phase 3 trials. The drug likely works by blocking inhibitory signals or enhancing immune cell activation, though the precise mechanism requires access to proprietary development data.","oneSentence":"JNS001 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:03.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01357993","phase":"PHASE3","title":"A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-05","conditions":"Attention-Deficit / Hyperactivity Disorder","enrollment":253},{"nctId":"NCT01323192","phase":"PHASE3","title":"An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-03","conditions":"Attention-Deficit Hyperactivity Disorder","enrollment":284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JNS001","genericName":"JNS001","companyName":"Janssen Pharmaceutical K.K.","companyId":"janssen-pharmaceutical-k-k","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}